$1.02▲ 0.00 (0.50%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.0× debt-to-equity).
revenue declining 9% year-over-year.
Quality
3.8
Health
8.1
Growth
2.6
Valuation
5
Sentiment
7.4
Analyst Target
—
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
46.1×
next 12 months est.
Market Cap
$143M
market capitalization
Div Yield
—
dividend yield
Profit Margin
-9.2%
net profit margin
Gross Margin
35.6%
revenue minus COGS
ROE
-5.9%
return on equity
Beta
1.84
vs S&P 500
52-Week Range
$1 — $2
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Organigram Global Inc. right now?
Organigram Global Inc.'s Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: revenue declining 9% year-over-year. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
Is OGI overvalued or undervalued?
Organigram Global Inc. (OGI) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 46.1×.
When does Organigram Global Inc. report its next earnings?
Organigram Global Inc.'s next earnings report is expected on approximately August 12, 2026.
What is Organigram Global Inc.'s profit margin?
Organigram Global Inc. has a net profit margin of -9.2%, indicating the company is currently operating at a net loss. Its gross margin stands at 35.6%, reflecting a more cost-intensive business model.
Is Organigram Global Inc.'s revenue growing?
Organigram Global Inc. is reporting revenue declining 8.9% year-over-year.
How much debt does Organigram Global Inc. have?
Organigram Global Inc. has a debt-to-equity ratio of 0.02×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 2.82×, indicating comfortable short-term liquidity.